Melanoma is one of the most common cancers in the United States and appears to be increasing in incidence.
1 x 1 Simard, E.P., Ward, E.M., Siegel, R., and Jemal, A. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin. 2012; 62: 118–128 Crossref | Scopus (430) | Google Scholar See all References
, 2 x 2 Cokkinides, V.E., Geller, A.C., and Jemal, A. Trends in melanoma mortality among non-Hispanic whites by educational attainment, 1993–2007. Arch Dermatol. 2012; 148: 587–591 Crossref | PubMed | Scopus (10) | Google Scholar See all References
, 3 x 3 Jemal, A., Saraiya, M., Patel, P., Cherala, S.S., Barnholtz-Sloan, J., Kim, J., Wiggins, C.L., and Wingo, P.A. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992–2006. J Am Acad Dermatol. 2011; 65: S17–S25 Abstract | Full Text | Full Text PDF | PubMed | Scopus (228) | Google Scholar See all References Although melanoma is the most aggressive form of skin cancer, it remains highly curable if it is detected early: 5-year survival is approximately 90% overall and exceeds 98% when disease is detected at the localized stage (84% of cases).
4 x 4 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al (eds). SEER Cancer Statistics Review 1975-2009. Table 16.8 Melanoma of the Skin (Invasive): 5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/browse_csr.php?section=16&page=sect_16_table.08.html. Accessed July 17, 2012. Google Scholar See all References However, approximately 4% of melanoma cases are diagnosed after distant metastasis, when 5-year survival is only 15%
4 x 4 Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al (eds). SEER Cancer Statistics Review 1975-2009. Table 16.8 Melanoma of the Skin (Invasive): 5-Year Relative and Period Survival (Percent) by Race, Sex, Diagnosis Year, Stage and Age. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975_2009_pops09/browse_csr.php?section=16&page=sect_16_table.08.html. Accessed July 17, 2012. Google Scholar See all References ; median survival in patients with metastatic disease is <1 year.
5 x 5 Altekruse, S.F., Kosary, C.L., Krapcho, M., Neyman, N., Aminou, R., and Waldron, W. 2010 SEER Cancer Statistics Review, 1975–2007. National Cancer Institute, Bethesda; 2010 Google Scholar See all References Increased knowledge of the molecular changes that drive cancer development can allow development of targeted therapeutics that can improve survival in patients with advanced melanoma.
6 x 6 Chapman, P.B., Hauschild, A., Robert, C., Haanen, J.B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., Hogg, D., Lorigan, P., Lebbe, C., Jouary, T., Schadendorf, D., Ribas, A., O’Day, S.J., Sosman, J.A., Kirkwood, J.M., Eggermont, A.M., Dreno, B., Nolop, K., Li, J., Nelson, B., Hou, J., Lee, R.J., Flaherty, K.T., and McArthur, G.A. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507–2516 Crossref | PubMed | Scopus (4607) | Google Scholar See all References
, 7 x 7 Hauschild, A., Grob, J.J., Demidov, L.V., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C.U., Miller, W.H. Jr., Kaempgen, E., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion-Sileni, V., Martin, A.M., Swann, S., Haney, P., Mirakhur, B., Guckert, M.E., Goodman, V., and Chapman, P.B. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380: 358–365 Abstract | Full Text | Full Text PDF | PubMed | Scopus (1657) | Google Scholar See all References